Facing Antibiotic Resistance, Bacteriophages or 'Killer' Viruses for Bacteria Are at the Starting Blocks in Lausanne

In Lausanne, a critical battle is brewing against the escalating threat of antibiotic resistance. For decades, antibiotics have been the frontline defense against bacterial infections, but their overuse and environmental spread have led to the alarming rise of multi-drug resistant (MDR) bacteria, particularly in hospital settings. This growing crisis has spurred a renewed search for alternative treatments, and attention is increasingly turning towards bacteriophages – natural predators of bacteria that inhabit virtually every corner of our planet.

Phagotherapy, the use of phages to treat infections, has a long history of empirical application in countries of the former Soviet Union, notably Georgia. However, Western European nations have largely eschewed this approach, demanding rigorous scientific proof of efficacy. This scientific caution, while understandable, has left a gap in treatment options as MDR bacteria become more prevalent. Fortunately, recent years have witnessed a significant resurgence in research on phagotherapy, with dedicated efforts underway in the United States and across Europe, including Switzerland.

This renewed focus on bacteriophages is not merely academic; it represents a tangible hope for overcoming the limitations of conventional antibiotics. The scientific community is now actively investigating the potential of these viruses as targeted weapons against specific bacterial strains. As research progresses and more evidence accumulates, phagotherapy is poised to move from the fringes of empirical practice to a scientifically validated therapeutic option. The work being done in Lausanne and elsewhere signifies a crucial step forward in developing innovative solutions to safeguard public health against the persistent and evolving challenge of bacterial infections.